Literature DB >> 2943994

A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence.

P A Easton, C Jadue, S Dhingra, N R Anthonisen.   

Abstract

We evaluated the effect of anticholinergic and beta-adrenergic inhaled bronchodilators, alone or in sequence, in 11 patients with chronic obstructive pulmonary disease. We compared the agents albuterol and ipratropium bromide when each was used as a single aerosol in the maximal dose. After giving a maximal dose of one agent, we compared the effect of adding the other with that of adding a placebo. When used alone, both bronchodilators significantly increased airflow and relieved hyperinflation, and there was no significant difference between the two. After the improvement with the initial bronchodilator, the subsequent effect of a second inhaled bronchodilator was not greater than that of placebo. These results suggest that in the treatment of chronic obstructive pulmonary disease, these two aerosols are usually equipotent in maximal doses and the addition of a second agent is of no practical value. The data support the prescription of a single inhaled agent in most cases but do not rule out the value of combinations of agents under special circumstances.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943994     DOI: 10.1056/NEJM198609183151205

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  14 in total

1.  Internal medicine: use of ipratropium bromide in chronic obstructive pulmonary disease.

Authors:  D P Tashkin
Journal:  West J Med       Date:  1987-09

Review 2.  Management of chronic obstructive pulmonary disease.

Authors:  S Kesten; A S Rebuck
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 3.  Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  A Ikeda; K Nishimura; T Izumi
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

4.  Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.

Authors:  D M Newnham; D P Dhillon; J H Winter; C M Jackson; R A Clark; B J Lipworth
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

Review 5.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  CMAJ       Date:  1988-03-15       Impact factor: 8.262

6.  Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.

Authors:  P Moayyedi; J Congleton; R L Page; S B Pearson; M F Muers
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

Review 7.  Complexities of diagnosis and treatment of allergic respiratory disease in the elderly.

Authors:  Paula J Busse; Kiran Kilaru
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?

Authors:  Chakravarthy B Reddy; Richard E Kanner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Comparison of one versus two bronchodilators in ventilated COPD patients.

Authors:  A Fernandez; J Muñoz; B de la Calle; I Alia; A Ezpeleta; M A de la Cal; A Reyes
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

10.  Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis.

Authors:  C P van Schayck; H Folgering; H Harbers; K L Maas; C van Weel
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.